NDAs Steffen Thirstrup, Director NDA Regulatory Advisory Board and Bill Richardson, Pharmacovigilance & Risk Management Expert, have been invited to present at the DIA Workshop on Benefit-Risk Strategy in Hotel Grand Majestic Plaza, Prague 15-16 June.

Professor Thirstrup will chair and Dr Richardson will reflect a number of case studies that clarify potential risk areas in Session 2: Implementing Benefit-Risk More Effectively.

The session will walk you through the do's and don’ts of benefit-risk implementation. The essential elements of the session are: – What benefit-risk information to include in the clinical overview – Choosing the right qualitative or quantitative framework.

To read more about the event click here.

Speaker

Steffen Thirstrup, MD

Advisory Board Director

Read more

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World